0GZX Stock Overview
Engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
DiaSorin S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €107.40 |
| 52 Week High | €112.10 |
| 52 Week Low | €76.24 |
| Beta | 0.19 |
| 11 Month Change | 5.09% |
| 3 Month Change | 4.68% |
| 1 Year Change | 22.49% |
| 33 Year Change | -42.06% |
| 5 Year Change | -9.67% |
| Change since IPO | 807.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0GZX | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 2.6% | -0.2% | 1.7% |
| 1Y | 22.5% | -2.3% | 8.3% |
Return vs Industry: 0GZX exceeded the UK Medical Equipment industry which returned -2.3% over the past year.
Return vs Market: 0GZX exceeded the UK Market which returned 8.3% over the past year.
Price Volatility
| 0GZX volatility | |
|---|---|
| 0GZX Average Weekly Movement | 29.7% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0GZX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0GZX's weekly volatility has increased from 15% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 3,186 | Carlo Rosa | diasoringroup.com/en |
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System.
DiaSorin S.p.A. Fundamentals Summary
| 0GZX fundamental statistics | |
|---|---|
| Market cap | €5.73b |
| Earnings (TTM) | €188.85m |
| Revenue (TTM) | €1.18b |
30.3x
P/E Ratio4.9x
P/S RatioIs 0GZX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0GZX income statement (TTM) | |
|---|---|
| Revenue | €1.18b |
| Cost of Revenue | €406.02m |
| Gross Profit | €772.19m |
| Other Expenses | €583.34m |
| Earnings | €188.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.54 |
| Gross Margin | 65.54% |
| Net Profit Margin | 16.03% |
| Debt/Equity Ratio | 42.6% |
How did 0GZX perform over the long term?
See historical performance and comparison